Top 20 Prescription Drugs of 2024

Shots: Driven by an endless pursuit of innovation, the biopharma industry is working tirelessly to bring new-age therapies to patients with serious health conditions and lifestyle-influenced diseases In 2023, the global prescription drug market size was valued at $1162.61B and is anticipated to reach $2151.63B by 2032 registering a CAGR of 7.1 %. Keytruda ranks 1st…

ByPrince GiriOctober 31, 2024

SPOTLIGHT

CXO Talks: Nick Kadysh the Founding CEO & President at PharmAla Biotech, in an Illuminating Dialogue Exchange with PharmaShots

In the second reprise of our Complimentary Exclusive Video Interview, we had the pleasure to speak with Nick Kadysh, the Founding CEO and President of PharmAla Biotech. Our complimentary exclusive video interview is an initiative to voice the global biopharma leaders by offering them a platform to shed light on the developments in the healthcare…

ByHimanshu SehgalAugust 12, 2024

INSIGHTS+

Know Your Investor: Invus (July’24 Edition)

Shots:   Backed with an evergreen investment strategy, Invus makes investments across several company stages ranging from early growth to turnarounds In 2023, Invus participated in 6 investment rounds in around 29 companies focusing on biopharma, manufacturing & services, and devices For a curated report on a specific investor or venture capital, reach out to us…

ByPrince GiriJuly 17, 2024

TOP 20

Top 20 Vaccines of 2024

Shots: Vaccines play an instrumental role in curbing infectious diseases by generating antibodies against antigens and creating a memory to defeat them. Several biopharma companies are steadfastly working to deliver vaccines against infectious and vaccine-preventable diseases around the world In 2024, the global vaccine market is estimated to be around $78B and is expected to…

ByPrince GiriJuly 11, 2024

TOP 20

Top 20 Biopharma Deal Terminations of 2023 Based on Total Deal Value

Shots: Sticking to M&A and licensing agreements can be really challenging, especially when dealing with stringent antitrust laws and evolving regulatory challenges. In such adverse scenarios, the rational and right step seems to be nullifying the existing deals. In 2023, the termination of the deal between Janssen and Arrowhead remained the talk of the town…

ByPrince GiriApril 18, 2024

TOP 20

Top 20 IPOs in Healthcare by Total Fund Value 2023

Shots: Clinical-stage biopharma companies are in constant need of funding and the best way to pull in money in such dire situations is by going public. 2023 had been a great year for Wall Streets across the globe with continuous announcements of IPOs Kenvue by bagging $4.37B upon completion of its IPO ranked first in…

ByPrince GiriMarch 28, 2024

INSIGHTS+

Know Your Investor (March Edition): Qiming Venture Partners

Shots: In this reprise, we feature Qiming Venture Partners again, based on the investments in 2023. With more than 600 investments to date, Qiming boasts a strong portfolio of companies involved in Technology & Consumer and Healthcare In 2023, Qiming closed 38 funding rounds comprising 11 in the first quarter, 10 in the second, 11…

BySenior EditorMarch 26, 2024

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in February 2024

Shots: The EMA approved 5 BLA and 8 New Chemical Entities in February 2024, leading to treatments for patients and advances in the healthcare industry In February 2024, the major highlighted drugs were Reblozyl to treat Transfusion-Dependent Anemia and Velsipity for the treatment of Severely Active Ulcerative Colitis PharmaShots has compiled a list of a total…

BySenior EditorMarch 20, 2024

INSIGHTS+

Know Your Investor (February Edition): F-Prime Capital Partners

Shots: Know Your Investor is an earnest effort from PharmaShots to acquaint our readers with leading Investors and venture capital firms in the healthcare industry Founded in 1969, F-Prime Capital Partners is a subsidiary of Fidelity Investments and primarily invests in healthcare and technology A total of 40 investments were closed by F-Prime in 2023,…

BySenior EditorFebruary 27, 2024

SPOTLIGHT

Spotlight Interview: David Esposito CEO at ONL Therapeutics in a Stimulating Conversation with PharmaShots

“Spotlight-Company of the Month” offers a unique platform for biopharma, life sciences, and healthcare companies, allowing them to connect with their target audiences and like-minded people. This month at PharmaShots’ Spotlight, we had an opportunity to engage in conversation with David Esposito CEO at ONL Therapeutics. David discusses the company's lead candidate ONL1204, which is…

ByHimanshu SehgalFebruary 19, 2024

Top 20 Prescription Drugs of 2024

CXO Talks: Nick Kadysh the Founding CEO & President at PharmAla Biotech, in an Illuminating Dialogue Exchange with PharmaShots

Know Your Investor: Invus (July’24 Edition)

Top 20 Vaccines of 2024

Top 20 Biopharma Deal Terminations of 2023 Based on Total Deal Value

Top 20 IPOs in Healthcare by Total Fund Value 2023

Know Your Investor (March Edition): Qiming Venture Partners

Insights+: EMA Marketing Authorization of New Drugs in February 2024

Know Your Investor (February Edition): F-Prime Capital Partners

Spotlight Interview: David Esposito CEO at ONL Therapeutics in a Stimulating Conversation with PharmaShots

Contact US

OUR INFORMATION

FOLLOW US